XML 71 R17.htm IDEA: XBRL DOCUMENT v3.20.4
Property, Plant and Equipment
 12 Months Ended
Dec. 31, 2020
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment Property, Plant and Equipment
Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows:
 As of December 31,
(In millions)20202019
Land$119.8 $118.1 
Buildings1,025.3 835.0 
Leasehold improvements104.6 99.5 
Machinery and equipment1,027.8 844.5 
Computer software and hardware903.0 798.4 
Furniture and fixtures62.5 58.3 
Construction in progress1,950.8 2,084.4 
Total cost5,193.8 4,838.2 
Less: accumulated depreciation(1,782.3)(1,590.9)
Total property, plant and equipment, net$3,411.5 $3,247.3 
Depreciation expense totaled $201.9 million, $190.6 million and $269.4 million for the years ended December 31, 2020, 2019 and 2018, respectively.
For the years ended December 31, 2020, 2019 and 2018, we capitalized interest costs related to construction in progress totaling approximately $65.2 million, $68.8 million and $54.0 million, respectively.
Solothurn, Switzerland Manufacturing Facility
In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational during the first half of 2021. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of December 31, 2020 and 2019, we had approximately $1.8 billion and $1.9 billion, respectively, capitalized as construction in progress related to this facility. For the year ended December 31, 2020, we placed approximately $256.8 million of fixed assets in service related to this facility.
Divestiture of Hillerød, Denmark Manufacturing Operations
In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hillerød, Denmark to FUJIFILM. This transaction included $631.5 million of property, plant and equipment, which was primarily comprised of $312.5 million for buildings and $287.3 million for machinery and equipment. For additional information on the divestiture of our Hillerød, Denmark manufacturing operations, please read Note 3, Divestitures, to these consolidated financial statements.